The FDA on March 29 approved the first over-the-counter naloxone product, Narcan nasal spray, which can reduce or reverse opioid overdoses.
“There are many over-the-counter preventive health medications that are covered by insurance, such as aspirin, vitamin D and fluoride,” Bobby Mukkamala, MD, chair of the AMA’s Substance Use and Pain Care Task Force, said in a statement. “Naloxone should be added to that list.”
Emergent BioSolutions, Narcan’s manufacturer, has yet to disclose how much it will charge for the over-the-counter version of the product, The Washington Post reported March 29.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
